DLA PIPER LLP (US)

Lobbying for CURRAX PHARMACEUTICALS LLC · Specialty pharmaceutical business

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · Tennessee · House · Senate · $50,000.00 income · posted Jul 21, 2025

Lobbying activity 1

Pharmacy

Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.